ArticleBMC geriatrics2026
Treatment outcomes and risk factors for unfavorable results among older asymptomatic pulmonary tuberculosis patients in China, 2021-2024.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTo understand the treatment outcomes and factors influencing unfavorable outcomes in older asymptomatic pulmonary tuberculosis patients (aPTB) in China, compare them with symptomatic patients, so as to provide a reference for further efforts in the prevention and treatment of asymptomatic tuberculosis in older people.
methodsData on older patients with asymptomatic pulmonary tuberculosis registered between 2021 and 2024 were obtained from the China Disease Prevention and Control Information System, including demographic characteristics, clinical features, and treatment management information. Descriptive epidemiological methods were employed to analyze the characteristics and treatment outcomes of the patients, and logistic regression models were used to identify factors influencing unfavorable treatment outcomes. Comparisons were also made with symptomatic patients during the same period.
resultsAsymptomatic patients accounted for 11.54% (25,735/223,014). Treatment success rates were comparable between aPTB and symptomatic pulmonary tuberculosis (sPTB) groups (90.83% vs. 90.55%, P = 0.142). However, among patients with unfavorable outcomes, aPTB patients had higher loss to follow-up (18.52% vs. 13.69%) and not evaluated rates, while sPTB patients had higher mortality (76.87% vs. 72.15%) and treatment failure. Independent risk factors for unfavorable outcomes in aPTB included advanced age (≥ 80 years: AOR = 3.30), western residence (AOR = 1.38), pathogen-positivity (AOR = 1.35), comorbidities (AOR = 1.72), retreatment (AOR = 1.27), non-standard regimens (AOR up to 1.81), non-use of fixed-dose combinations (AOR = 1.18), no initial follow-up visit (AOR = 1.80), and adverse drug reactions (AOR = 6.58). Active case finding (AOR = 0.64) and high adherence (AOR = 0.02-0.06) were associated with lower odds of unfavorable outcomes.
conclusionsOlder aPTB patients constitute a notable proportion with treatment success comparable to sPTB patients, but exhibit distinct patterns of unfavorable outcomes. Multiple factors (such as advanced age ≥ 80 years, comorbidities, adverse drug reactions, and non-standard regimens) were associated with unfavorable outcomes within this surveillance cohort, supporting targeted interventions for this overlooked population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.